Jonas Grossman - 01 Dec 2022 Form 4 Insider Report for Renovacor, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2022, 20:23:28 UTC
Prior SEC filing: 12 Oct 2022
Next SEC filing: 13 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Joseph Carroll, as attorney-in-fact

Key filing fact

Jonas Grossman filed Form 4 for Renovacor, Inc. on 05 Dec 2022.

Key facts

This page summarizes Jonas Grossman's Form 4 filing for Renovacor, Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Dec 2022, 20:23.

Change

Previous filing in this sequence was filed on 12 Oct 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCOR transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -394,657
Change %: -100%
Price
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCOR transaction Derivative

Stock Option

Disposed to Issuer

Transaction value: $0
Shares: -24,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,000
Exercise price
Footnotes: F2, F3

RCOR transaction Derivative

Stock Option

Disposed to Issuer

Transaction value: $0
Shares: -12,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jonas Grossman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement") in exchange for 69,578 shares of Rocket common stock having a market value of $18.39 per share on the effective date of the merger.

Footnote F2

Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.

Footnote F3

Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.